A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

Essential Roles of mTOR/Akt Pathway in Aurora-A Cell Transformation

(2012) Makoto Taga et al.   International Journal of Biological Sciences

A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors

(2011) D. Mahadevan et al.   ANNALS OF ONCOLOGY

Aurora B kinase inhibition in mitosis: Strategies for optimizing the use of Aurora kinase inhibitors such as AT9283

(2011) Jayne Curry et al.   CELL CYCLE

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

(2010) E. Claire Dees et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics

(2010) T. Macarulla et al.   MOLECULAR CANCER THERAPEUTICS

Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer

(2010) A Pohl et al.   PHARMACOGENOMICS JOURNAL

A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer

(2009) J. Michels et al.   ANNALS OF ONCOLOGY

Expression of Aurora B and alternative variant forms in hepatocellular carcinoma and adjacent tissue

(2009) Mahmut Yasen et al.   CANCER SCIENCE

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

(2009) R. B. Cohen et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors

(2009) Neeltje Steeghs et al.   JOURNAL OF CLINICAL ONCOLOGY

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells

(2009) Christopher D Scharer et al.   Journal of Translational Medicine

Aurora Kinases as Anticancer Drug Targets

(2008) O. Gautschi et al.   CLINICAL CANCER RESEARCH

Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma

(2008) Abhijit Mazumdar et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity†

(2008) Steven Howard et al.   JOURNAL OF MEDICINAL CHEMISTRY